NCI-H292 Xenograft Model Service for NSCLC

The NCI-H292 xenograft model is a well-established preclinical platform for evaluating therapeutic strategies against lung mucoepidermoid carcinoma, a rare salivary gland-type NSCLC subtype characterized by the CRTC1::MAML2 fusion and EGFR wild-type overexpression. Alfa Cytology offers a comprehensive NCI-H292 xenograft model service designed to accelerate your oncology drug discovery pipeline, providing robust in vivo data from tumor establishment through endpoint analysis with rigorous quality control and regulatory-compliant reporting.

Overview of NCI-H292 Xenograft Model for NSCLC

Non-small cell lung cancer (NSCLC) encompasses a diverse spectrum of histological subtypes, among which mucoepidermoid carcinoma (MEC) represents a rare but clinically significant salivary gland-type tumor. MEC of the lung is characterized by the presence of mucous cells, epidermoid cells, and intermediate cells, and is molecularly defined by recurrent chromosomal translocations—most notably the CRTC1::MAML2 fusion resulting from t(11;19)(q21;p13). The NCI-H292 cell line, originally established in 1982 from a lymph node metastasis of a 32-year-old Black female patient with lung mucoepidermoid carcinoma, faithfully recapitulates this disease entity both genomically and phenotypically. NCI-H292 harbors the pathognomonic CRTC1::MAML2 fusion, an NF2 frameshift mutation (p.Pro496Thrfs*8), and exhibits low-level microsatellite instability (MSI-low), while retaining wild-type status for EGFR, KRAS, and TP53. The cell line is mucin-rich and overexpresses MUC5AC, consistent with its mucoepidermoid origin, and demonstrates overexpression of wild-type EGFR, making it a relevant model for evaluating EGFR-targeted therapies in fusion-driven NSCLC.

Fig 1. a-Hederin inhibits proliferation of human lung cancer cells. (Fang, Cong, et al., 2021)

Cell line-derived xenograft (CDX) models utilizing NCI-H292 cells provide a reproducible and physiologically relevant preclinical system for assessing tumor growth kinetics, drug efficacy, resistance mechanisms, pharmacokinetics, and biomarker responses. When implanted into immunodeficient mice, NCI-H292 cells reliably form tumors that histologically resemble the original biopsy specimen, recapitulating the mucoepidermoid morphology and molecular features of human disease. The model has been extensively utilized to evaluate EGFR-targeted agents including erlotinib and cetuximab, combination regimens with docetaxel, Hsp90 inhibitors, and novel bispecific antibodies such as amivantamab. These models serve as a critical bridge between in vitro screening and clinical translation, enabling researchers to generate high-confidence efficacy data for MEC-directed and EGFR-targeted agents prior to advancing compounds into more complex development stages.

Cell Line Information: NCI-H292

The NCI-H292 cell line is a well-characterized human lung mucoepidermoid carcinoma cell line that serves as a robust foundation for preclinical xenograft studies. Below is a comprehensive summary of its biological and culture characteristics:

Our Services

At Alfa Cytology, we leverage our extensive expertise in preclinical oncology model development to deliver validated NCI-H292 xenograft studies with rapid turnaround times and comprehensive data packages. Our integrated service platform spans from tumor establishment and in-life monitoring through histopathological and molecular endpoint analysis, ensuring that your mucoepidermoid carcinoma-directed or EGFR-targeted compound receives rigorous, publication-quality evaluation in a clinically relevant NSCLC setting.

Workflow of NCI-H292 Xenograft Model Construction

The construction of a reliable NCI-H292 xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth, consistent pharmacological responses, and regulatory-compliant data generation. Each study is initiated with thorough cell line authentication and host animal health screening, followed by systematic tumor implantation, monitoring, and endpoint analysis.

1. Cell Line Preparation and Quality Control: NCI-H292 cells are recovered from cryopreserved stocks and expanded under standardized culture conditions (RPMI 1640 + 10% FBS, 37°C, 5% CO₂). Prior to inoculation, cells undergo mycoplasma testing, STR authentication, and viability assessment to confirm identity and ensure optimal engraftment potential.
2. Host Mouse Selection and Acclimatization: Immunodeficient mouse strains—most commonly athymic nude (nu/nu), NOD-SCID, or NSG (NOD-scid IL2Rγnull) mice—are selected based on study objectives and immune requirements. Animals are acclimatized for a minimum of 5–7 days under controlled environmental conditions with health monitoring and body weight baseline recording.
3. Tumor Cell Inoculation: Log-phase NCI-H292 cells are harvested, washed, and resuspended in phosphate-buffered saline (PBS) or PBS/Matrigel mixture (typically 1:1 v/v). For subcutaneous models, 1 × 10⁶ to 5 × 10⁶ cells in a volume of 100–200 µL are injected into the right flank. Orthotopic models involve intrathoracic injection to recapitulate the native tumor microenvironment and metastatic behavior.
4. Tumor Growth Monitoring and Randomization: Tumor development is monitored by caliper measurement twice weekly, with tumor volume calculated using the modified ellipsoid formula (V = 0.5 × length × width²). Mice are randomized into treatment groups when tumors reach a palpable volume of 100–200 mm³, ensuring balanced baseline tumor sizes across cohorts. Body weight and clinical signs are recorded concurrently.
5. Treatment Administration and In-Life Assessment: Test articles are administered according to the predefined dosing regimen (route, frequency, and duration). Tumor volume and body weight are measured at regular intervals throughout the treatment period. Tumor growth inhibition (TGI), tumor growth delay (TGD), and partial or complete response rates are calculated relative to vehicle-treated controls.
6. Endpoint Analysis and Data Reporting: At study termination, tumors are excised, weighed, and processed for downstream analyses. Standard endpoints include hematoxylin and eosin (H&E) histopathology, immunohistochemistry (IHC) for proliferation (Ki-67) and apoptosis (cleaved caspase-3) markers, mucin staining (PAS/Alcian blue), EGFR pathway analysis, pharmacokinetic/pharmacodynamic (PK/PD) assessment, and biomarker profiling. A comprehensive study report with statistical analysis is delivered to the client.

Fig 2. NCI-H292 xenograft model construction workflow.

Case Study-NCI-H292 Xenograft Model Development

In a representative preclinical study, NCI-H292 cells were successfully engrafted into immunodeficient mice to evaluate the efficacy of a novel therapeutic candidate targeting EGFR-overexpressing mucoepidermoid carcinoma. Following subcutaneous inoculation, tumors established consistently with a take rate exceeding 90%, reaching the target volume range within 10–14 days. Treatment cohorts received the investigational compound via oral gavage or intravenous injection on a defined schedule, while vehicle controls received the formulation buffer. Tumor growth was monitored biweekly via caliper measurement, and body weights were recorded to assess treatment tolerability. At study endpoint, excised tumors were subjected to comprehensive histopathological and molecular characterization, revealing dose-dependent reductions in tumor burden, decreased Ki-67 proliferation indices, and elevated apoptotic markers. Pharmacokinetic sampling confirmed adequate systemic exposure, and the overall data package supported the compound's advancement into subsequent preclinical development stages. These findings demonstrate the utility of the NCI-H292 xenograft model as a robust platform for generating translational efficacy data in mucoepidermoid NSCLC.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor, operational efficiency, and client-centric flexibility to deliver preclinical xenograft studies that meet the highest standards of the pharmaceutical and biotechnology industries. Our NCI-H292 NSCLC xenograft service is designed to accelerate your drug discovery timeline while ensuring data integrity and regulatory readiness.

• Expertise in salivary gland-type NSCLC models: Our scientific team has deep experience with mucoepidermoid carcinoma biology and understands the nuances of modeling this rare NSCLC subtype, including CRTC1::MAML2 fusion-driven tumorigenesis and EGFR wild-type overexpression.
• Validated, authenticated cell lines: All NCI-H292 stocks are STR-authenticated, mycoplasma-negative, and maintained under rigorous quality control to ensure batch-to-batch consistency and reliable tumor engraftment.
• Flexible study design: We accommodate diverse dosing regimens, combination therapy protocols, biomarker-driven endpoints, and custom analytical requirements tailored to your compound's mechanism of action and development stage.
• Comprehensive endpoint portfolio: From standard tumor growth inhibition and histopathology to advanced molecular profiling, PK/PD integration, and biomarker validation, we provide a full spectrum of analytical capabilities.
• Regulatory-compliant operations: Our vivarium and laboratories operate under IACUC-approved protocols with adherence to GLP-like standards, ensuring data packages suitable for IND-enabling and regulatory submissions.
• Rapid study initiation and reporting: Typical NCI-H292 xenograft studies can be initiated within 2–4 weeks of contract execution, with comprehensive draft reports delivered promptly after study completion.

Contact Us

Ready to advance your mucoepidermoid carcinoma or EGFR-targeted therapeutic program with a validated NCI-H292 xenograft model? Contact us today to discuss your study requirements, receive a customized project proposal, and learn how Alfa Cytology can accelerate your preclinical oncology research. Our team of experienced scientists is standing by to design a study protocol that aligns with your discovery objectives and delivers actionable, high-quality data.

For research use only. Not intended for any clinical use.